Isomorphic Labs

London-based Isomorphic Labs, the AI-first drug discovery company spun out of Google DeepMind, has secured a historic £1.6 billion ($2.1 billion) Series B funding round led by Thrive Capital.

Summary of transaction details:

• Value: £1.6 billion ($2.1 billion)
• Sector: Healthcare & Biotech / MedTech
• Advisor: Not disclosed
• Key Entities: Target: Isomorphic Labs; Lead Investor: Thrive Capital; Participating Investors: Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund
• Location: London, UK

Note: Founded by Sir Demis Hassabis, Isomorphic Labs is on a mission to "solve all disease" by transitioning from pioneering AI models to applying them at industrial scale. This capital injection focuses on the deployment of IsoDDE, the firm's proprietary AI drug design engine. The platform has already hit key milestones across internal programs with "unprecedented speed" and supports major strategic partnerships with industry titans including Novartis, Eli Lilly, and Johnson & Johnson. The funding follows a £462.3 million raise in April 2025 and will be used to accelerate therapeutic pipelines toward clinical trials while scaling global hiring for AI, engineering, and clinical talent.